Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...
Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.
Mayo Clinic in Jacksonville, Fla., offers a minimally invasive procedure to stabilize bones weakened by metastatic cancer, a technique available at few U.S. centers. The photodynamic bone ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Patients with bone metastases due to urothelial carcinoma had worse outcomes than those without bone ...
Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases ...
SAN ANTONIO -- Prophylactic radiotherapy (RT) for asymptomatic bone metastases significantly reduced the rate of skeletal-related events (SREs) in patients with cancer, according to a small randomized ...
BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for patients with bone metastases from breast cancer, and also appeared to be ...
Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice? Bone metastases are a major cause of morbidity for men with prostate cancer. Complications of bone metastases include ...
In most cases, breast cancer with bone metastasis is incurable. Now, corresponding author Venu Raman, Ph.D., and his team say they have developed a potential novel treatment that is specific to breast ...
The FEATURE study provides the first prospective validation of FDG-PET/CT and PERCIST response criteria in patients presenting with bone-only or bone-dominant metastatic breast cancer, opening the ...
Rechallenge with trabectedin in patients with locally advanced or metastatic soft tissue sarcoma following drug holiday: The experience of the French Sarcoma Group (FSG). This is an ASCO Meeting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results